These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 28340378

  • 1. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection.
    Ruiz-Ceja KA, Chirino YI.
    Biomed Pharmacother; 2017 Jun; 90():24-37. PubMed ID: 28340378
    [Abstract] [Full Text] [Related]

  • 2. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R.
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [Abstract] [Full Text] [Related]

  • 3. Targeted therapies for non-small cell lung cancer.
    Dempke WC, Suto T, Reck M.
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
    Falconi A, Lopes G, Parker JL.
    J Thorac Oncol; 2014 Feb; 9(2):163-9. PubMed ID: 24419412
    [Abstract] [Full Text] [Related]

  • 8. NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.
    Liu K, Chen HL, Gu MM, You QS.
    J Chemother; 2016 Jun; 28(3):225-9. PubMed ID: 25971309
    [Abstract] [Full Text] [Related]

  • 9. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
    Albaba H, Lim C, Leighl NB.
    Pharmacoeconomics; 2017 Dec; 35(12):1195-1209. PubMed ID: 28861770
    [Abstract] [Full Text] [Related]

  • 10. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P, Pazdur R.
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [Abstract] [Full Text] [Related]

  • 11. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z, Wang Z, Liu X, Wang D.
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [Abstract] [Full Text] [Related]

  • 12. Current status of targeted therapy in non-small cell lung cancer.
    Parums DV.
    Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
    [Abstract] [Full Text] [Related]

  • 13. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
    Lin TC, Tsai LH, Chou MC, Chen CY, Lee H.
    Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
    [Abstract] [Full Text] [Related]

  • 14. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [Abstract] [Full Text] [Related]

  • 15. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K, Yuan Q.
    J Cancer Res Ther; 2016 Dec 15; 12(Supplement):C131-C137. PubMed ID: 28230005
    [Abstract] [Full Text] [Related]

  • 16. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Liu Y, Wang S, Dong QZ, Jiang GY, Han Y, Wang L, Wang EH.
    Med Oncol; 2016 Mar 15; 33(3):22. PubMed ID: 26820570
    [Abstract] [Full Text] [Related]

  • 17. Current Molecularly Targeting Therapies in NSCLC and Melanoma.
    Rajanna S, Rastogi I, Wojdyla L, Furo H, Kulesza A, Lin L, Sheu B, Frakes M, Ivanovich M, Puri N.
    Anticancer Agents Med Chem; 2015 Mar 15; 15(7):856-68. PubMed ID: 25642982
    [Abstract] [Full Text] [Related]

  • 18. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.
    J Thorac Oncol; 2013 Feb 15; 8(2):161-70. PubMed ID: 23287853
    [Abstract] [Full Text] [Related]

  • 19. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
    Cottini F, Lautenschlaeger T.
    Cancer J; 2013 Feb 15; 19(3):263-71. PubMed ID: 23708073
    [Abstract] [Full Text] [Related]

  • 20. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
    Larkins E, Scepura B, Blumenthal GM, Bloomquist E, Tang S, Biable M, Kluetz P, Keegan P, Pazdur R.
    Oncologist; 2015 Nov 15; 20(11):1320-5. PubMed ID: 26446239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.